Profile data is unavailable for this security.
About the company
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
- Revenue in CHF (TTM)531.74m
- Net income in CHF100.68m
- Incorporated1971
- Employees1.78k
- LocationBachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
- Phone+41 619352333
- Fax+41 619352324
- Websitehttp://www.bachem.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dechra Pharmaceuticals plc | 817.96m | 45.13m | 3.28bn | 2.04k | 71.03 | 3.45 | 22.23 | 4.01 | 0.359 | 0.359 | 6.52 | 7.39 | 0.4975 | 1.67 | 6.87 | 356,974.50 | 2.74 | 3.55 | 3.06 | 4.00 | 57.15 | 56.74 | 5.52 | 7.22 | 1.40 | 11.54 | 0.3779 | 96.35 | 12.14 | 13.67 | 4.86 | 17.39 | 48.50 | 15.93 |
Krka d.d. Novo Mesto | 1.70bn | 359.71m | 3.41bn | 11.49k | 8.98 | 1.54 | 7.24 | 2.00 | 11.69 | 11.69 | 55.25 | 68.38 | 0.6575 | 1.47 | 3.94 | -- | 13.92 | 12.26 | 16.84 | 14.67 | 56.73 | 57.50 | 21.17 | 18.04 | 2.42 | -- | 0.0055 | -- | 9.69 | 6.28 | 17.49 | 18.94 | -3.27 | -- |
Dottikon ES Holding AG | 283.87m | 74.30m | 3.53bn | 670.00 | 46.93 | 4.61 | 37.44 | 12.45 | 5.38 | 5.38 | 20.55 | 54.73 | 0.3166 | 0.4641 | 5.14 | 426,878.20 | 8.29 | 6.73 | 9.67 | 7.56 | 75.59 | 81.91 | 26.17 | 19.64 | 1.78 | -- | 0.0383 | -- | 15.09 | 10.67 | 13.33 | 21.75 | 23.13 | -- |
Richter Gedeon Vegyeszeti Gyar Nyrt | 2.07bn | 400.50m | 3.58bn | 12.18k | 8.94 | 1.32 | 6.76 | 1.73 | 835.11 | 835.11 | 4,308.65 | 5,646.29 | 0.6459 | 2.40 | 4.34 | -- | 12.65 | 10.19 | 14.53 | 11.64 | 57.36 | 56.21 | 19.59 | 16.56 | 2.35 | -- | 0.0142 | -- | 27.30 | 12.56 | 11.43 | 77.28 | 12.38 | -- |
Hikma Pharmaceuticals Plc | 2.32bn | 173.00m | 4.16bn | 8.84k | 24.74 | 2.11 | 11.87 | 1.80 | 0.6757 | 0.6757 | 9.15 | 7.93 | 0.5693 | 1.70 | 3.36 | 232,942.90 | 4.32 | 9.13 | 5.68 | 12.54 | 50.26 | 50.86 | 7.59 | 15.51 | 1.14 | 6.70 | 0.3739 | 31.08 | -1.41 | 5.39 | -55.34 | -- | 8.30 | 1.43 |
Grifols SA | -99.01bn | -99.01bn | 5.28bn | 23.25k | -- | 0.9631 | -- | -- | -- | -- | -- | 9.04 | -- | -- | -- | -- | -- | 3.21 | -- | 4.03 | -- | 41.82 | -- | 9.75 | 0.7425 | -- | 0.5355 | -- | 22.92 | 7.03 | 10.36 | -20.66 | 3.06 | -- |
DiaSorin SpA | -99.01bn | -99.01bn | 5.65bn | 3.35k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.63 | -- | 19.02 | -- | 67.86 | -- | 24.99 | -- | -- | -- | 25.24 | 40.43 | 16.80 | 25.46 | 22.58 | 25.68 | 5.59 |
Orion Oyj | 1.33bn | 346.05m | 5.82bn | 3.53k | 16.76 | 6.42 | 14.86 | 4.38 | 2.48 | 2.48 | 9.53 | 6.48 | 1.02 | 1.69 | 7.54 | 380,096.40 | 26.71 | 20.40 | 32.78 | 25.57 | 63.32 | 60.43 | 26.08 | 21.15 | 2.04 | -- | 0.1907 | 92.50 | 28.78 | 5.34 | 80.34 | 9.79 | -0.9051 | 1.99 |
BACHEM HOLDING AG | 531.74m | 100.68m | 6.44bn | 1.78k | 63.02 | 5.41 | 48.08 | 12.12 | 1.36 | 1.36 | 7.21 | 15.87 | 0.3965 | 1.24 | 3.83 | 299,403.70 | 7.51 | 9.31 | 8.45 | 11.22 | 32.21 | 31.61 | 18.93 | 19.39 | 2.75 | 8.77 | 0.0006 | 58.79 | 5.66 | 15.24 | -12.21 | 19.24 | 24.80 | 6.40 |
Swedish Orphan Biovitrum AB (publ) | 1.66bn | 232.86m | 6.68bn | 1.56k | 27.65 | 2.73 | 14.98 | 4.03 | 8.84 | 8.84 | 63.00 | 89.61 | 0.3715 | 1.41 | 4.33 | -- | 5.21 | 7.46 | 6.80 | 9.46 | 74.58 | 76.38 | 14.03 | 19.58 | 0.5303 | 9.15 | 0.2555 | 0.00 | 21.00 | 23.61 | -1.53 | 18.09 | 60.32 | -- |
Recordati Industria Chimica e Farma SpA | 1.83bn | 309.25m | 8.04bn | 4.30k | 25.87 | 5.16 | 18.53 | 4.38 | 1.50 | 1.50 | 8.90 | 7.52 | 0.5439 | 1.74 | 5.53 | -- | 9.17 | 12.82 | 11.86 | 16.38 | 69.42 | 71.05 | 16.85 | 22.48 | 0.8114 | 15.90 | 0.5261 | 61.84 | 17.29 | 7.55 | -19.08 | 1.58 | 45.87 | 6.23 |
Ipsen SA | 3.13bn | 587.34m | 8.64bn | 5.74k | 15.45 | 2.57 | 9.34 | 2.76 | 6.74 | 7.32 | 34.75 | 40.45 | 0.5956 | 2.10 | 5.27 | -- | 11.20 | 9.91 | 14.78 | 13.80 | 83.28 | 82.00 | 18.81 | 15.23 | 1.58 | 47.09 | 0.1904 | 21.11 | 5.24 | 9.43 | -8.26 | 17.05 | 0.9854 | 3.71 |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 10 Mar 2023 | 3.70m | 5.02% |
Premier Fund Managers Ltd.as of 30 Nov 2022 | 945.97k | 1.28% |
BlackRock Investment Management (UK) Ltd.as of 28 Feb 2023 | 923.97k | 1.25% |
VV Verm�gensverwaltung AGas of 30 Nov 2022 | 870.88k | 1.18% |
The Vanguard Group, Inc.as of 03 Mar 2023 | 817.37k | 1.11% |
Capital Research & Management Co. (Global Investors)as of 31 Dec 2022 | 773.48k | 1.05% |
UBS Asset Management Switzerland AGas of 28 Feb 2023 | 691.02k | 0.94% |
Vontobel Asset Management AGas of 28 Feb 2023 | 678.10k | 0.92% |
Credit Suisse Asset Management (Schweiz) AGas of 28 Feb 2023 | 583.80k | 0.79% |
abrdn Investment Management Ltd.as of 28 Feb 2022 | 560.79k | 0.76% |